Emerging Multi-Drug Eutectics: Opportunities and Challenges

doi:10.1208/s12249-021-01939-6

Review

. 2021 Feb 7;22(2):66.

doi: 10.1208/s12249-021-01939-6.

Emerging Multi-Drug Eutectics: Opportunities and Challenges

Jamshed Haneef¹, Shakir Ali², Renu Chadha³

Affiliations

¹ Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110 062, India. jamshedhaneef@jamiahamdard.ac.in.
² Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110 062, India.
³ University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Studies (CAS), Panjab University, Chandigarh, 160 014, India.

PMID: 33554308
DOI: 10.1208/s12249-021-01939-6

Review

Emerging Multi-Drug Eutectics: Opportunities and Challenges

Jamshed Haneef et al. AAPS PharmSciTech. 2021.

. 2021 Feb 7;22(2):66.

doi: 10.1208/s12249-021-01939-6.

Authors

Jamshed Haneef¹, Shakir Ali², Renu Chadha³

Affiliations

¹ Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110 062, India. jamshedhaneef@jamiahamdard.ac.in.
² Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110 062, India.
³ University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Studies (CAS), Panjab University, Chandigarh, 160 014, India.

PMID: 33554308
DOI: 10.1208/s12249-021-01939-6

Abstract

Complexity and heterogeneous nature of most diseases have posed greater challenges in the modern healthcare system. Fixed-dose combination can offer an ideal way to improve patient compliance and higher therapeutic efficacy. However, biopharmaceutical issues associated with the drug combinations remain unaddressed. Multidrug eutectics (MDE) have demonstrated significant promise in improving the biopharmaceutical attributes with synergistic therapeutic action. Eutectic mixtures are the multicomponent solid forms that possess lesser melting point than the individual components at a fixed composition. Non-covalent linking of drug combinations as MDE is an innovative strategy with enhanced solubility, dissolution, and mechanical and potential therapeutic efficacy. This review provides a comprehensive overview of the design of MDE, rational selection of drugs, characterization tools, and their therapeutic potential. Besides, the futuristic perspective where MDE could make a significant impact on combination therapy is briefly outlined. Graphical Abstract.

Keywords: crystal engineering; eutectic mixtures; fixed-dose combination; non-covalent derivative; thermal analysis.

PubMed Disclaimer

Cited by

Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations.
Górniak A, Złocińska A, Trojan M, Pęcak A, Karolewicz B. Górniak A, et al. Pharmaceutics. 2022 Apr 22;14(5):912. doi: 10.3390/pharmaceutics14050912. Pharmaceutics. 2022. PMID: 35631498 Free PMC article.
Drug Nanocrystals in Oral Absorption: Factors That Influence Pharmacokinetics.
Macedo LO, Masiero JF, Bou-Chacra NA. Macedo LO, et al. Pharmaceutics. 2024 Aug 29;16(9):1141. doi: 10.3390/pharmaceutics16091141. Pharmaceutics. 2024. PMID: 39339178 Free PMC article. Review.

References

1. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26(5):331-342. https://doi.org/10.1046/j.1365-2710.2001.00363.x .
1. Pourkavoos N. Unique risks, benefits, and challenges of developing drug–drug combination products in a pharmaceutical industrial setting. Comb Prod Ther. 2012;2(1):2. https://doi.org/10.1007/s13556-012-0002-2 . - DOI
1. Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14(5):1125–36. https://doi.org/10.5114/aoms.2018.77561 . - DOI - PubMed - PMC
1. Kumar V, Prasad B, Singh S. Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discov Today: Ther Strateg. 2008;5(1):63–71. https://doi.org/10.1016/j.ddstr.2008.03.001 . - DOI
1. Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265–76. https://doi.org/10.3109/10837450.2012.660699 . - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations

[1] Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26(5):331-342. https://doi.org/10.1046/j.1365-2710.2001.00363.x .

[2] Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26(5):331-342. https://doi.org/10.1046/j.1365-2710.2001.00363.x .

[3] Pourkavoos N. Unique risks, benefits, and challenges of developing drug–drug combination products in a pharmaceutical industrial setting. Comb Prod Ther. 2012;2(1):2. https://doi.org/10.1007/s13556-012-0002-2 . - DOI

[4] Pourkavoos N. Unique risks, benefits, and challenges of developing drug–drug combination products in a pharmaceutical industrial setting. Comb Prod Ther. 2012;2(1):2. https://doi.org/10.1007/s13556-012-0002-2 . - DOI

[5] Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14(5):1125–36. https://doi.org/10.5114/aoms.2018.77561 . - DOI - PubMed - PMC

[6] Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14(5):1125–36. https://doi.org/10.5114/aoms.2018.77561 . - DOI - PubMed - PMC

[7] Kumar V, Prasad B, Singh S. Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discov Today: Ther Strateg. 2008;5(1):63–71. https://doi.org/10.1016/j.ddstr.2008.03.001 . - DOI

[8] Kumar V, Prasad B, Singh S. Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discov Today: Ther Strateg. 2008;5(1):63–71. https://doi.org/10.1016/j.ddstr.2008.03.001 . - DOI

[9] Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265–76. https://doi.org/10.3109/10837450.2012.660699 . - DOI - PubMed

[10] Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265–76. https://doi.org/10.3109/10837450.2012.660699 . - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Emerging Multi-Drug Eutectics: Opportunities and Challenges

Affiliations

Emerging Multi-Drug Eutectics: Opportunities and Challenges

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources